Cargando…

Differentiating between Laryngopharyngeal Dysesthesia and Hypersensitivity Reactions to Oxaliplatin and Addressing Dyspnea: 2 Case Reports

Oxaliplatin is a key drug for colorectal cancer and causes peripheral neuropathy. Oxaliplatin-induced laryngopharyngeal dysesthesia is an acute peripheral neuropathy similar to a hypersensitivity reaction. Hypersensitivity reactions to oxaliplatin do not require immediate discontinuation, but re-cha...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawaguchi, Fumitaka, Aoyama, Takeshi, Tsuneki, Takafumi, Kaneko, Kentaro, Kawamura, Ryoichiro, Sato, Hiroki, Kobayashi, Michiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176188/
https://www.ncbi.nlm.nih.gov/pubmed/37187686
http://dx.doi.org/10.1159/000530336
_version_ 1785040379412742144
author Kawaguchi, Fumitaka
Aoyama, Takeshi
Tsuneki, Takafumi
Kaneko, Kentaro
Kawamura, Ryoichiro
Sato, Hiroki
Kobayashi, Michiko
author_facet Kawaguchi, Fumitaka
Aoyama, Takeshi
Tsuneki, Takafumi
Kaneko, Kentaro
Kawamura, Ryoichiro
Sato, Hiroki
Kobayashi, Michiko
author_sort Kawaguchi, Fumitaka
collection PubMed
description Oxaliplatin is a key drug for colorectal cancer and causes peripheral neuropathy. Oxaliplatin-induced laryngopharyngeal dysesthesia is an acute peripheral neuropathy similar to a hypersensitivity reaction. Hypersensitivity reactions to oxaliplatin do not require immediate discontinuation, but re-challenge and desensitization therapy can be very burdensome for patients. We encountered 2 cases in which laryngopharyngeal dysesthesia could be differentiated from hypersensitivity reactions to oxaliplatin, and treatment could continue. The first case was that of a 58-year-old woman who developed dyspnea during the first course of combination therapy with capecitabine and oxaliplatin as the primary treatment for advanced rectal cancer. After laryngopharyngeal dysesthesia was differentiated from hypersensitivity reaction based on these typical symptoms, she was considered to have grade 3 (Common Terminology Criteria for Adverse Events [CTCAE] ver. 5) laryngopharyngeal dysesthesia. The second course of oxaliplatin was extended from 2 to 4 h, but symptoms recurred. The third course was performed with a reduced dose of oxaliplatin from 130 mg/m(2) to 100 mg/m(2), and the patient could complete the treatment without symptom recurrence. The second case involved a 76-year-old woman who developed grade 3 laryngopharyngeal dysesthesia during the first course of combination therapy with capecitabine and oxaliplatin as the primary treatment for localized colon cancer. Based on the experience of the first case, we reduced the oxaliplatin dose from 130 mg/m(2) to 100 mg/m(2) for the second course, and the patient completed the treatment without symptoms. This dose reduction was effective for grade 3 laryngopharyngeal dysesthesia caused by oxaliplatin without reducing therapeutic efficacy.
format Online
Article
Text
id pubmed-10176188
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-101761882023-05-13 Differentiating between Laryngopharyngeal Dysesthesia and Hypersensitivity Reactions to Oxaliplatin and Addressing Dyspnea: 2 Case Reports Kawaguchi, Fumitaka Aoyama, Takeshi Tsuneki, Takafumi Kaneko, Kentaro Kawamura, Ryoichiro Sato, Hiroki Kobayashi, Michiko Case Rep Oncol Case Report Oxaliplatin is a key drug for colorectal cancer and causes peripheral neuropathy. Oxaliplatin-induced laryngopharyngeal dysesthesia is an acute peripheral neuropathy similar to a hypersensitivity reaction. Hypersensitivity reactions to oxaliplatin do not require immediate discontinuation, but re-challenge and desensitization therapy can be very burdensome for patients. We encountered 2 cases in which laryngopharyngeal dysesthesia could be differentiated from hypersensitivity reactions to oxaliplatin, and treatment could continue. The first case was that of a 58-year-old woman who developed dyspnea during the first course of combination therapy with capecitabine and oxaliplatin as the primary treatment for advanced rectal cancer. After laryngopharyngeal dysesthesia was differentiated from hypersensitivity reaction based on these typical symptoms, she was considered to have grade 3 (Common Terminology Criteria for Adverse Events [CTCAE] ver. 5) laryngopharyngeal dysesthesia. The second course of oxaliplatin was extended from 2 to 4 h, but symptoms recurred. The third course was performed with a reduced dose of oxaliplatin from 130 mg/m(2) to 100 mg/m(2), and the patient could complete the treatment without symptom recurrence. The second case involved a 76-year-old woman who developed grade 3 laryngopharyngeal dysesthesia during the first course of combination therapy with capecitabine and oxaliplatin as the primary treatment for localized colon cancer. Based on the experience of the first case, we reduced the oxaliplatin dose from 130 mg/m(2) to 100 mg/m(2) for the second course, and the patient completed the treatment without symptoms. This dose reduction was effective for grade 3 laryngopharyngeal dysesthesia caused by oxaliplatin without reducing therapeutic efficacy. S. Karger AG 2023-05-12 /pmc/articles/PMC10176188/ /pubmed/37187686 http://dx.doi.org/10.1159/000530336 Text en © 2023 The Author(s). Published by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Case Report
Kawaguchi, Fumitaka
Aoyama, Takeshi
Tsuneki, Takafumi
Kaneko, Kentaro
Kawamura, Ryoichiro
Sato, Hiroki
Kobayashi, Michiko
Differentiating between Laryngopharyngeal Dysesthesia and Hypersensitivity Reactions to Oxaliplatin and Addressing Dyspnea: 2 Case Reports
title Differentiating between Laryngopharyngeal Dysesthesia and Hypersensitivity Reactions to Oxaliplatin and Addressing Dyspnea: 2 Case Reports
title_full Differentiating between Laryngopharyngeal Dysesthesia and Hypersensitivity Reactions to Oxaliplatin and Addressing Dyspnea: 2 Case Reports
title_fullStr Differentiating between Laryngopharyngeal Dysesthesia and Hypersensitivity Reactions to Oxaliplatin and Addressing Dyspnea: 2 Case Reports
title_full_unstemmed Differentiating between Laryngopharyngeal Dysesthesia and Hypersensitivity Reactions to Oxaliplatin and Addressing Dyspnea: 2 Case Reports
title_short Differentiating between Laryngopharyngeal Dysesthesia and Hypersensitivity Reactions to Oxaliplatin and Addressing Dyspnea: 2 Case Reports
title_sort differentiating between laryngopharyngeal dysesthesia and hypersensitivity reactions to oxaliplatin and addressing dyspnea: 2 case reports
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176188/
https://www.ncbi.nlm.nih.gov/pubmed/37187686
http://dx.doi.org/10.1159/000530336
work_keys_str_mv AT kawaguchifumitaka differentiatingbetweenlaryngopharyngealdysesthesiaandhypersensitivityreactionstooxaliplatinandaddressingdyspnea2casereports
AT aoyamatakeshi differentiatingbetweenlaryngopharyngealdysesthesiaandhypersensitivityreactionstooxaliplatinandaddressingdyspnea2casereports
AT tsunekitakafumi differentiatingbetweenlaryngopharyngealdysesthesiaandhypersensitivityreactionstooxaliplatinandaddressingdyspnea2casereports
AT kanekokentaro differentiatingbetweenlaryngopharyngealdysesthesiaandhypersensitivityreactionstooxaliplatinandaddressingdyspnea2casereports
AT kawamuraryoichiro differentiatingbetweenlaryngopharyngealdysesthesiaandhypersensitivityreactionstooxaliplatinandaddressingdyspnea2casereports
AT satohiroki differentiatingbetweenlaryngopharyngealdysesthesiaandhypersensitivityreactionstooxaliplatinandaddressingdyspnea2casereports
AT kobayashimichiko differentiatingbetweenlaryngopharyngealdysesthesiaandhypersensitivityreactionstooxaliplatinandaddressingdyspnea2casereports